Topical therapy of various dermatoses with ImpoyzTM (clobetasol propionate) cream 0.025%

Authors

  • Mahendra Haribhai Vaghasiya Department of Dermatology, Shri Hari Skin Care, Surat, Gujarat, India
  • Sanjay Kumar Dayani Department of Dermatology, Skin Care Clinic, Nagpur, Maharashtra, India
  • Ravi Munasing Rathod Department of Dermatology, Skin Care Center, Hubli, Karnataka, India
  • Arun Kumar Chatterjee Department of Dermatology, Skin Care Clinic, Patparganj, Delhi, India
  • Balachandra S. Ankad Department of Dermatology, S. Nijalingappa Medical College, Bagalkot, Karnataka, India
  • Saleem Abdulhasanbeg Jamadar Department of Dermatology, Jamadar's Skin Care Clinic, Gadag-Betageri, Karnataka, India
  • Umesh Omkarlal Agrawal Department of Dermatology, Priyal Skin Care Clinic, Dahod, Gujarat, India
  • Jayesh Sanaryia Amrutlal Department of Dermatology, Sparsh Skin and Cosmetic Clinic, Morbi, Gujarat, India
  • Mahendra Kumar Singhi Department of Dermatology, Singhi Clinic, Jodhpur, Rajasthan, India
  • Mashkoor Ahmed Wani Department of Dermatology, Shah Multispeciality Clinic, Thane, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20220438

Keywords:

Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Abstract

The most widely prescribed drugs for the treatment of a variety of dermatoses are Topical corticosteroids (TC). These medications are approved for the treatment of inflammatory and pruritic manifestations of dermatologic disorders due to their powerful symptom-relieving impact. Clobetasol propionate (CP) is the most popular (TC) used to relieve itching, redness, and oedema caused by a variety of skin disorders. Anti-inflammatory, anti-pruritic, and vasoconstrictive characteristics are all present in it. CP works by binding to cytoplasmic glucocorticoid receptors and activating glucocorticoid receptor-mediated gene expression, resulting in the production of anti-inflammatory proteins while suppressing the production of inflammatory mediators. The formulation is free from known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, and has demonstrated hypoallergenic effects. The efficacy, safety, and clinical experience of utilizing CP 0.025% cream for the treatment of various dermatologic disorders are discussed in this case series.

 

References

Das A, Panda S. Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach. Indian J Dermatol. 2017;62(3):237-50.

Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(3):36-46.

Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. Treasure Island, FL: StatPearls Publishing; 2022.

Rosso JQ. Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Sidgiddi S, Naqvi SMH, Shenoy M, Balraj DN, Kothari J, Gupta S, et al. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. Dermatol Ther (Heidelb). 2021;11(5):1717-32.

Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):15354.

Downloads

Published

2022-02-23

Issue

Vol. 9 No. 3 (2022): March 2022

Section

Case Series